Inhibiting intracellular CD28 in cancer cells enhances antitumor immunity and overcomes anti-PD-1 resistance via targeting PD-L1

10.1016/j.ccell.2024.11.008

Affiliations
Zhen Yang, Xinpeng Liu, Jun Zhu, Yangyang Chai, Boyi Cong, Bo Li, Wanfeng Gao, Ye Hu, Mingyue Wen, Yanfang Liu, Li Fu, Xuetao Cao

DOI: 10.1016/j.ccell.2024.11.008

Abstract
Deciphering mechanisms for cancer immune escape may provide targets for improving immunotherapy efficacy. By in vivo genome-wide CRISPR loss-of-function screening in a mouse model of triple negative breast cancer (TNBC), we uncovered a non-classical function of Cd28 in cancer cells to promote immune escape. Knocking out Cd28 in cancer cells increased infiltration of type I conventional DC (cDC1) and activated tumor-specific CD8

Keywords
CD8(+) T cell, PD-L1, anti-PD-1 therapy, antitumor immunity, cancer cell CD28, mRNA stability

関連製品

カタログ番号	製品名	説明	ターゲット
HV974083	PD-L1	Anti-Human CD274/PD-L1/B7-H1 Antibody (SP263) [SP263] (HV974083) is a mouse monoclonal antibody detecting B7-H1 in IHC. Suitable for Human.	B7-H1, Programmed cell death 1 ligand 1, PDCD1 ligand 1, PDCD1L1, B7 homolog 1, PDCD1LG1, PDL1, hPD-L1, Programmed death ligand 1, B7H1, PD-L1, CD274

組換えタンパク質

抗体

アッセイキット

Inhibiting intracellular CD28 in cancer cells enhances antitumor immunity and overcomes anti-PD-1 resistance via targeting PD-L1

クイックアクセス

お問い合わせ